Optimized Manufacturing of 4,4,5,5,5-Pentafluoro-1-Pentanol via US6002053A Patent

• US6002053A enables a scalable, two-step synthesis of 4,4,5,5,5-Pentafluoro-1-pentanol with >97% GC purity and up to 88% isolated yield.
• The patented route avoids hazardous reagents (e.g., tributyltin hydride) and ultrasound, enhancing safety and industrial feasibility.
• NINGBO INNO PHARMCHEM CO.,LTD. offers bulk supply of this fluorinated intermediate with full COA, industrial purity ≥99%, and GMP-aligned documentation.

4,4,5,5,5-Pentafluoro-1-pentanol (CAS 148043-73-6), also known as pentafluoropentanol or 4,4,5,5,5-pentafluoropentanol, is a critical fluorinated building block in the synthesis of fulvestrant—a steroidal antiestrogen used in metastatic breast cancer therapy. Its unique perfluoroalkyl chain imparts metabolic stability and lipophilicity, making it indispensable in modern pharmaceutical development. However, achieving high industrial purity (>99%) at scale requires a robust, reproducible manufacturing process. The US Patent US6002053A provides precisely such a methodology, now leveraged by leading global manufacturers like NINGBO INNO PHARMCHEM CO.,LTD. for commercial production.

Breakdown of the US6002053A Patent Methodology

The patented process (US6002053A) outlines an efficient two-step synthesis starting from readily available perfluoroethyl iodide and allyl alcohol. Unlike earlier literature routes, this method eliminates toxic reagents and complex equipment while delivering superior yields and purity.

Step 1: Radical Addition to Form 4,4,5,5,5-Pentafluoro-2-iodo-1-pentanol

In the first stage, perfluoroethyl iodide undergoes free-radical addition to allyl alcohol under mild conditions. Key features include:

• Radical Initiator: Sodium dithionite/sodium bicarbonate (preferred) or cyclopentadienyliron dicarbonyl dimer—both acyl-free systems that avoid side reactions.
• Solvent System: Acetonitrile/water mixtures (e.g., 1800 mL MeCN + 1400 mL H₂O per 440 g perfluoroethyl iodide).
• Temperature Control: Initial addition at –10 to –5°C, then gradual warming to room temperature.
• Yield & Purity: Up to 80% isolated yield with 99% GC purity (Example 1), suitable for direct use in Step 2 without purification.

Step 2: Catalytic Hydrogenolytic Dehalogenation

The iodinated intermediate is then converted to the target alcohol via hydrogenation:

• Catalyst: 5% Pd/C (0.01–0.1 wt% metal loading)—significantly lower than PtO₂-based methods.
• Acid Scavenger: Triethylamine or ethanolamine to neutralize HI byproduct.
• Diluent: Ethyl acetate, methyl tert-butyl ether, or aqueous alkanolamine systems.
• Conditions: 40–60 bar H₂, 0–50°C, 12–24 h reaction time.
• Final Output: 88% yield of 4,4,5,5,5-Pentafluoro-1-pentanol with 99.9% GC purity (Example 6).

This streamlined approach ensures consistent quality ideal for API synthesis. When sourcing high-purity 4,4,5,5,5-Pentafluoro-1-pentanol, buyers should prioritize suppliers capable of executing this validated route under controlled conditions.

Advantages Over Alternative Synthetic Routes

Historically, three main routes existed for synthesizing pentafluoropentanol—all with significant drawbacks:

Method	Key Limitations	US6002053A Advantage
Propargyl alcohol + Na₂S₂O₄ → PtO₂ hydrogenation	Requires 2.5 g PtO₂ per 30 g product; costly catalyst	Uses 0.1% Pd/C; 25x less precious metal
Ultrasound-promoted cuprate addition	46% yield; acetylene risk; complex setup	No ultrasound; 80%+ yield; inherently safer
Tributyltin hydride dehalogenation	Toxic Sn residues; not scalable	Tin-free; fully scalable to multi-kilogram batches

Moreover, commercial samples often report only ~95% purity—insufficient for GMP pharmaceutical synthesis. The US6002053A process reliably achieves ≥99% purity, meeting stringent regulatory requirements for intermediates in oncology APIs.

Implementing Patented Processes Under Licensing Agreements

While US6002053A is a granted U.S. patent, its claims are specific to the combination of (1) acyl-free radical initiation and (2) catalytic hydrogenolysis with acid binder. Companies seeking to manufacture 4,4,5,5,5-Pentafluoro-1-pentanol at scale must either license the technology or ensure their process design falls outside the claim scope.

For B2B buyers, partnering with established manufacturers who already operate under compliant frameworks reduces legal and technical risk. NINGBO INNO PHARMCHEM CO.,LTD., as a premier global manufacturer of fluorinated intermediates, offers this compound with full documentation—including COA, SDS, and PS—ensuring traceability and batch-to-batch consistency. Their production adheres to the optimized parameters of US6002053A, delivering material suitable for direct use in fulvestrant synthesis and other advanced applications.

With competitive bulk price structures and supply capacity exceeding 5 metric tons annually, NINGBO INNO PHARMCHEM CO.,LTD. supports both clinical-stage developers and commercial API producers requiring high-integrity 4,4,5,5,5-pentafluoropentanol.